康芝藥業(300086.SZ):布洛芬顆粒中標第三批全國藥品集採
格隆匯 8 月 25日丨康芝藥業(300086.SZ)公佈,根據《國務院辦公廳關於印發國家組織藥品集中採購和使用試點方案》(國辦發【2019】2號)和《國家醫療保障局等九部門關於國家組織藥品集中採購和使用試點擴大區域範圍的實施意見》(醫保發[2019]56號有關精神),聯合採購辦公室開展了第三批國家組織藥品集中採購和使用工作。2020年8月20日,公司全資子公司河北康芝製藥有限公司(“河北康芝”)參加了第三批全國藥品集中採購的投標,河北康芝已通過國家藥品監督管理局仿製藥質量和療效一致性評價的布洛芬顆粒中標此次集中採購。根據有關中標規則,此次中標的標期為3年,3年約定採購量預計為2000萬袋左右。
此次集中採購是國家組織的第三批藥品集中帶量採購,採購週期中,醫療機構將優先使用此次藥品集中採購中選藥品,並確保完成約定採購量。若公司後續簽訂採購合同並實施後,將填補該產品在醫療機構市場的銷售空白,並有利於擴大布洛芬顆粒的銷售規模,同時擴充合作渠道,促進公司有關產品市場的開拓,進一步擴大相關產品的銷售,提高市場佔有率,提升公司的品牌影響力,對公司的未來經營業績將產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.